By Chris Wack
CalciMedica shares were down 5%, to $2.16, after the company said it has entered into a credit facility with Avenue Venture Opportunities Fund II, a fund of Avenue Capital Group, providing up to $32.5 million.
The biopharmaceutical company said proceeds from the facility are intended to support the continued development of its product pipeline.
The credit agreement, which has a term of 3 1/2 years, includes an initial tranche of $10 million fully funded at close and additional tranches of up to $22.5 million available to the company subject to certain milestones.
There is no minimum cash requirement, nor other financial covenants, in the agreement. With the proceeds from the first tranche of this facility, CalciMedica's cash position is expected to fund current operations into the middle of 2026.
CalciMedica shares hit their 52-week low of $1.86 Tuesday, and are down 53% in the past 12 months.
Write to Chris Wack at chris.wack@wsj.com
(END) Dow Jones Newswires
March 05, 2025 12:47 ET (17:47 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。